A hot young section of the industry is seeing some consolidation already, as Alnylam Pharmaceuticals Inc. merged with its counterpart in Germany, Ribopharma AG, and concurrently raised $24.6 million in private financing to build a bigger, stronger entity. (BioWorld Today) Read More
